Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)
Brief Summary: The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras wildtype metastatic colorectal cancer patients.


Options:
A: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: FOLFIRI | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: FOLFIRI | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 1, 2
C: Arm Label: 1Capecitabine-irinotecan; Type: ACTIVE_COMPARATOR; Interventions: Drug: capecitabine-irinotecan | Arm Label: 2capecitabine plus irinotecan; Type: EXPERIMENTAL; Interventions: Drug: capecitabine+irinotecan (1st line) | Intervention Type: DRUG; Name: capecitabine-irinotecan; Assigned to Arm(s): 1Capecitabine-irinotecan | Intervention Type: DRUG; Name: capecitabine+irinotecan (1st line); Assigned to Arm(s): 2capecitabine plus irinotecan
D: Arm Label: Safety part: EMD 525797 250 mg + Standard of Care (SoC); Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 250 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 500 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 500 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 750 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 750 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 1000 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 1000 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized part: EMD 525797 500 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 500 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized Part: EMD 525797 1000 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 1000 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized Part: SoC; Type: OTHER; Interventions: Drug: Cetuximab, Drug: Irinotecan | Intervention Type: DRUG; Name: EMD 525797 250 mg; Assigned to Arm(s): Safety part: EMD 525797 250 mg + Standard of Care (SoC) | Intervention Type: DRUG; Name: EMD 525797 500 mg; Assigned to Arm(s): Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 500 mg + SoC | Intervention Type: DRUG; Name: EMD 525797 750 mg; Assigned to Arm(s): Safety part: EMD 525797 750 mg + SoC | Intervention Type: DRUG; Name: EMD 525797 1000 mg; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 1000 mg + SoC | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Randomized Part: SoC, Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 250 mg + Standard of Care (SoC), Safety part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 750 mg + SoC | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Randomized Part: SoC, Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 250 mg + Standard of Care (SoC), Safety part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 750 mg + SoC

Answer: D